Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pyridostigmine in Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2 Infection

NCT04343963 is registered in ClinicalTrials.gov with Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran as lead sponsor.

NCT NCT04343963
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04343963 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pyridostigmine in Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2 Infection
Lead sponsor
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Phase
Phase 2/3
Overall status
Unknown status
Start date
April 4, 2020
Completion date
April 30, 2021
Enrollment
436 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, sars-cov-2